TEVA:NYE-Teva Pharmaceutical Industries Limited American Depositary Shares (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 17.11

Change

-0.26 (-1.50)%

Market Cap

USD 38.25B

Volume

7.40M

Analyst Target

USD 12.19
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its products include Copaxone, Azilect and Provigil.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.08 (+1.77%)

USD 79.77B
TAK Takeda Pharmaceutical Co Ltd A..

+0.02 (+0.15%)

USD 45.03B
HLN Haleon plc

-0.05 (-0.54%)

USD 43.99B
RDY Dr. Reddy’s Laboratories Ltd..

-0.21 (-1.42%)

USD 12.67B
CTLT Catalent Inc

-0.10 (-0.17%)

USD 10.78B
ELAN Elanco Animal Health

+0.07 (+0.50%)

USD 6.96B
BHC Bausch Health Companies Inc

-0.35 (-3.83%)

USD 3.37B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.22 (-2.38%)

USD 2.80B
CPHI China Pharma Holdings Inc

N/A

USD 3.43M
YCBD cbdMD Inc

-0.05 (-9.04%)

USD 1.73M

ETFs Containing TEVA

ISRA VanEck Israel ETF 8.99 % 0.60 %

-0.02 (-0.08%)

USD 0.08B
FLWR:SW 5.80 % 0.00 %

N/A

N/A
ISRPF iShares Public Limited Co.. 5.39 % 0.00 %

-0.36 (-0.08%)

USD 2.22B
IDVO Amplify International Enh.. 3.02 % 0.00 %

-0.02 (-0.08%)

USD 0.14B
ALFI 0.00 % 0.88 %

N/A

N/A
EIS iShares MSCI Israel ETF 0.00 % 0.59 %

+0.14 (+-0.08%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
GWL 0.00 % 0.34 %

N/A

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.33 (+-0.08%)

N/A
ISRCF iShares V Public Limited .. 0.00 % 0.00 %

+0.03 (+-0.08%)

N/A
ISRHF iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ISRUF iShares V Public Limited .. 0.00 % 0.00 %

+0.06 (+-0.08%)

N/A
ISRZF iShares II Public Limited.. 0.00 % 0.00 %

-0.19 (-0.08%)

N/A
ISRIF 0.00 % 0.00 %

N/A

N/A
ISRVF 0.00 % 0.00 %

N/A

N/A
ISRWF 0.00 % 0.00 %

N/A

N/A
ISRNF 0.00 % 0.00 %

N/A

N/A
ISRRF 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 63.89% 80% B- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.89% 80% B- 95% A
Trailing 12 Months  
Capital Gain 92.03% 73% C 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 92.03% 73% C 95% A
Trailing 5 Years  
Capital Gain 82.60% 79% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.60% 79% B- 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.42% 60% D- 62% D
Dividend Return 8.42% 47% F 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.93% 53% F 25% F
Risk Adjusted Return 21.63% 60% D- 38% F
Market Capitalization 38.25B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector